Ep45: Jay Bradner

Episode Summary

Executive Summary: Jay Bradner traces his path from curious Harvard student to president of Novartis Institutes for Biomedical Research, emphasizing that chemistry, biology, and medicine are best advanced through open, collaborative science. He discusses building chemical biology at Dana-Farber, the impact of bromodomain and protein-degradation work, and how leading a global R&D organization requires trust, focus, and patient-centered prioritization.

Main Topics: From Midwestern upbringing to scientific curiosity (Priority: 4/5): Bradner describes growing up in Chicago, a family shaped by intellectual support and hardship, and an early split interest in literature and biochemistry that led him toward chemical biology. Training across medicine, chemistry, and oncology (Priority: 5/5): He explains how Harvard, the University of Chicago, Brigham/Dana-Farber, and Schreiber’s lab gave him a translational perspective on disease, drug discovery, and cancer medicine. Open-source chemical biology and bromodomain discovery (Priority: 5/5): Bradner details the choice to share JQ1 and related bromodomain tools broadly, arguing that replication, connectivity, and community acceleration outweighed proprietary advantage. Cancer, pancreatic disease, and therapeutic urgency (Priority: 5/5): His father’s pancreatic cancer and the limits of then-available oncology drugs sharpened his commitment to finding better therapeutic approaches for hard targets like KRAS, MYC, and p53 pathways. Moving from academia to Novartis leadership (Priority: 4/5): Bradner recounts the unexpected Novartis offer and why the scale, resources, and potential for impact made the move compelling despite limited prior management experience. Leading NIBR: trust, prioritization, and portfolio discipline (Priority: 5/5): He reflects on learning that leadership is about trust and communication, and on making hard strategic cuts to focus Novartis R&D on the most promising programs and platforms. Next-generation enabling technologies and talent development (Priority: 4/5): He highlights DNA-encoded libraries, targeted protein degradation, AAV capabilities, analytics, and postdoctoral fellowships as ways to improve discovery and train future drug hunters.

Key Arguments: Science is inherently creative, not rote; Bradner’s path through literature and chemistry shows that scientific work can combine imagination with rigor. Open science can accelerate discovery more effectively than proprietary hoarding, because replication and broad use produce faster validation and better community learning. Chemical biology is especially powerful when it yields tools that help reveal human biology before becoming medicines. The biggest therapeutic opportunities often lie in hard, validated targets that are difficult to drug, not merely in easy low-hanging fruit. Leadership in large R&D organizations is less about having all the ideas and more about earning trust, communicating clearly, and supporting teams. Large-scale portfolio management requires discipline: fewer sites, fewer therapeutic areas, and sharper focus can improve strategic coherence. Modern platforms such as DNA-encoded libraries and targeted protein degradation can expand the reach of drug discovery toward historically undruggable biology. Training postdocs and early-career scientists inside industry is valuable because it develops future drug hunters and keeps the organization intellectually sharp.

Data Points: NIBR workforce: 6,000 scientists - Bradner describes Novartis Institutes for Biomedical Research as a global discovery organization. NIBR headquarters workforce: About 2,500 scientists - He specifies the Cambridge research headquarters size within the broader organization. Novartis overall R&D spend: Almost $9 billion annually - Bradner explains the scale of Novartis research investment. NIBR budget: $2.6 billion - He says NIBR manages roughly this share of Novartis’s R&D budget. Research sites: 6 sites worldwide - Bradner notes the distributed global footprint of NIBR science. Therapeutic areas: 8 therapeutic areas - He lists the major disease areas NIBR works across. Drug discovery projects after restructuring: Reduced from 430 to 340 - He describes portfolio contraction as part of a strategic reset. Research areas exited: 4 therapeutic areas - Bradner discusses refocusing the portfolio. Sites closed: 2 research sites - He explains operational streamlining after joining Novartis. Leases wound down: 6 or more - Part of the restructuring and footprint reduction. Molecule distribution: More than 500 laboratories - He says JQ1 and related bromodomain tools were shared broadly. Publication output: About 200 papers in 8 years - He cites the broad scientific output generated around the open-science effort. Clinical-stage bromodomain inhibitors: 12 - He notes downstream therapeutic activity that followed BRD4/JQ1 work. JQ1 screening space molecules: From 1.8 million to almost 2 billion - He describes growth in searchable chemistry via DNA-encoded library technology. Postdoc program: Innovation Postdoctoral Fellowship - Bradner announces this as a training pathway for drug discovery careers.

Pivotal Quotes: "We could put the chemical structure out there. We could put the full synthetic pathway out there. We could put grams of material into the public domain..." — Jay Bradner: Explaining the open-source decision behind the bromodomain inhibitor JQ1 and the lab’s public-sharing strategy. "Leadership now maps closest back to trust. Trust being the absence of doubt." — Jay Bradner: His definition of effective leadership after moving from academia to running a large global research organization. "If we could be scooped by another laboratory, that our idea was not original enough." — Jay Bradner: Describing the standard his lab used to judge whether an idea was sufficiently novel and worth pursuing.

Implications: The episode argues for more open, collaborative, patient-driven drug discovery and for leadership that prioritizes trust and focus. It also signals that industry and academia can cross-pollinate to train the next generation of drug hunters.